Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PURPOSE: B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. PATIENTS A...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Davids, Matthew S., Roberts, Andrew W., Seymour, John F., Pagel, John M., Kahl, Brad S., Wierda, William G., Puvvada, Soham, Kipps, Thomas J., Anderson, Mary Ann, Salem, Ahmed Hamed, Dunbar, Martin, Zhu, Ming, Peale, Franklin, Ross, Jeremy A., Gressick, Lori, Desai, Monali, Kim, Su Young, Verdugo, Maria, Humerickhouse, Rod A., Gordon, Gary B., Gerecitano, John F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2017
Onderwerpen:
ORIGINAL REPORTS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455685/
https://ncbi.nlm.nih.gov/pubmed/28095146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.4320
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items